Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study

被引：0
|
作者：
Hartung, H-P [1 ,2 ]
Arnold, D. L. [3 ]
Cohen, J. A. [4 ,5 ]
Coles, A. J. [6 ]
Fox, E. J. [7 ]
Havrdova, E. [8 ]
Selmaj, K. W. [9 ]
Margolin, D. H. [10 ]
Palmer, J. [10 ]
Oyuela, P. [10 ]
Panzara, M. A. [10 ]
Compston, D. A. S. [11 ]
机构：
[1] Univ Dusseldorf, Dept Neurol, Dusseldorf, Germany
[2] Univ Dusseldorf, Ctr Neuropsychiat, Dusseldorf, Germany
[3] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[4] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA
[6] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England
[7] Univ Texas Med Branch, Round Rock, TX USA
[8] Charles Univ Prague, Dept Neurol, Sch Med 1, Prague, Czech Republic
[9] Med Univ Lodz, Dept Neurol, Lodz, Poland
[10] Genzyme, Cambridge, MA USA
[11] Univ Cambridge, Dept Clin Neurosci, Cambridge, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P043
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study
    Vucic, S.
    Coles, A. J.
    Arnold, D. L.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 821 - 821
  • [2] Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: four-year follow-up of the CARE-MS I study
    Coles, A. J.
    Arnold, D. L.
    Cohen, J. A.
    Fox, E. J.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 107 - 108
  • [3] Efficacy and Safety of Alemtuzumab in Treatment-Naive Patients with Relapsing-Remitting MS: Four-Year Follow-up of the CARE-MS I Study
    Macdonell, R. A. L.
    Coles, A. J.
    Arnold, D. L.
    Hartung, H-P.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 806 - 806
  • [4] Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II)
    Havrdova, E.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 235 - 235
  • [5] Alemtuzumab improves MRI outcomes in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: three-year follow-up of CARE-MS II
    Fisher, E.
    Barkhof, F.
    Cohen, J. A.
    Fox, E. J.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 113 - 114
  • [6] Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II
    Moreau, T.
    Margolin, D. H.
    Kasten, L.
    Singer, B.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 86 - 86
  • [7] Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up
    Fox, Edward
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Twyman, Cary
    Vladic, Anton
    Margolin, David
    Oyuela, Pedro
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [8] Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
    Annette F. Okai
    Lilyana Amezcua
    Regina R. Berkovich
    Angel R. Chinea
    Keith R. Edwards
    Brian Steingo
    Aljoeson Walker
    Alan K. Jacobs
    Nadia Daizadeh
    Mitzi J. Williams
    Neurology and Therapy, 2019, 8 : 367 - 381
  • [9] Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II
    Arroyo Gonzalez, R.
    Moreau, T.
    Cohen, J. A.
    Giovannoni, G.
    Margolin, D. H.
    Kasten, L.
    Havrdova, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 614 - 614
  • [10] Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
    Okai, Annette F.
    Amezcua, Lilyana
    Berkovich, Regina R.
    Chinea, Angel R.
    Edwards, Keith R.
    Steingo, Brian
    Walker, Aljoeson
    Jacobs, Alan K.
    Daizadeh, Nadia
    Williams, Mitzi J.
    NEUROLOGY AND THERAPY, 2019, 8 (02) : 367 - 381
12345